Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Hook

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Science & Justice : Journal of the Forensic Science Society|July 18, 2024
Bloodstain classification methods: A critical review and a look to the futureEmma Hook, Sarah Fieldhouse, David Flatman-Fairs, et al.
Forensic Science International|January 17, 2026
Bloodstain classification methods: What methods do analysts use, why, and how accurate are they?Emma Hook, Sarah Fieldhouse, David Flatman-Fairs, et al.
Pharmacoeconomics|July 28, 2023
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Pharmacoeconomics|March 12, 2025
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Targeted Oncology|March 16, 2024
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UKRachael Batteson, Emma Hook, Hollie Wheat, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Science & Justice : Journal of the Forensic Science Society|July 18, 2024
Bloodstain classification methods: A critical review and a look to the futureEmma Hook, Sarah Fieldhouse, David Flatman-Fairs, et al.
Forensic Science International|January 17, 2026
Bloodstain classification methods: What methods do analysts use, why, and how accurate are they?Emma Hook, Sarah Fieldhouse, David Flatman-Fairs, et al.
Pharmacoeconomics|July 28, 2023
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Pharmacoeconomics|March 12, 2025
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Targeted Oncology|March 16, 2024
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UKRachael Batteson, Emma Hook, Hollie Wheat, et al.
Pageof 1